{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:29:33Z","timestamp":1774358973015,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clindermatol.2020.12.013","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:04:44Z","timestamp":1608152684000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Autoimmune connective tissue diseases in the COVID-19 pandemic"],"prefix":"10.1016","volume":"39","author":[{"given":"Lyubomir","family":"Dourmishev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrina","family":"Guleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Pozharashka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kossara","family":"Drenovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyubka","family":"Miteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snejina","family":"Vassileva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.12.013_bib0001","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1971400916639605","article-title":"Imaging of connective tissue diseases of the head and neck","volume":"29","author":"Abdel Razek","year":"2016","journal-title":"Neuroradiol J"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0002","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2017.10.003","article-title":"Biomarkers in connective tissue diseases","volume":"140","author":"Jog","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0004","series-title":"Coronavirus disease 2019 (COVID-19)","year":"2020"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0005","series-title":"Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), 2020","year":"2020"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-017-0657-5","article-title":"Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies","volume":"19","author":"Teruel","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108410","article-title":"Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients","volume":"215","author":"Sawalha","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0008","article-title":"The cytokine storm and COVID-19","author":"Hu","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0009","article-title":"SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0011","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0013","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/jir.2011.0071","article-title":"Interferon alpha as a primary pathogenic factor in human lupus","volume":"31","author":"Niewold","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40257-020-00514-2","article-title":"Managing cutaneous immune-mediated diseases during the COVID-19 pandemic","volume":"21","author":"Torres","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/ajd.13295","article-title":"Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases","volume":"61","author":"Rademaker","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0016","article-title":"COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs","author":"Ansarin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0018","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.169.3.987","article-title":"Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile","volume":"169","author":"Yee","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0019","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17539","article-title":"Assessment of lupus anticoagulant positivity in patients with Coronavirus disease 2019 (COVID-19)","volume":"3","author":"Reyes Gil","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0021","doi-asserted-by":"crossref","DOI":"10.5152\/eurjrheum.2020.20055","article-title":"Coronavirus disease-2019: implication for the care and management of patients with systemic lupus erythematosus","author":"Sawalha","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0022","first-page":"577","article-title":"Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology?","volume":"38","author":"Elefante","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0023","first-page":"e13776","article-title":"Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy","author":"Vezzoli","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0024","article-title":"Patients with lupus with COVID-19: University of Michigan experience","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/annrheumdis-2020-217566","article-title":"Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3904\/kjim.2016.234","article-title":"Infection in systemic lupus erythematosus, similarities, and differences with lupus flare","volume":"32","author":"Jung","year":"2017","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0027","article-title":"Corticosteroids for treating sepsis","volume":"2015","author":"Annane","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/pde.14202","article-title":"Systemic immunosuppressive therapy for inflammatory skin diseases in children: expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic","volume":"37","author":"Reynolds","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.clindermatol.2020.12.013_bib0029","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/ajd.13313","article-title":"COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian\/New Zealand consensus statement","volume":"61","author":"Wang","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10354-017-0595-x","article-title":"Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology","volume":"168","author":"Dourmishev","year":"2018","journal-title":"Wien Med Wochenschr"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2020.12.013_bib0031","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/0961203396005001051","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0032","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0002-9343(90)90345-E","article-title":"Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids","volume":"89","author":"Wallace","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/096120339600500524","article-title":"In vivo models of thrombosis for the antiphospholipid syndrome","volume":"5","author":"Pierangeli","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0034","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3899\/jrheum.090994","article-title":"Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus","volume":"37","author":"Penn","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms8010085","article-title":"The use of antimalarial drugs against viral infection","volume":"8","author":"D'Alessandro","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0038","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0040","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2665-9913(20)30089-8","article-title":"Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology","volume":"2","author":"Owens","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0041","series-title":"Advisory on the use of hydroxychloroquine as prophylaxis for SARSCoV2 infection","year":"2020"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0042","unstructured":"Writing Group of the Johns Hopkins University and Johns Hopkins Hospital COVID-19 Treatment Guidance Working Group. JHMI Clinical Guidance for Available Pharmacologic Therapies for COVID-19. Available at: https:\/\/www.hopkinsguides.com\/hopkins\/ub?cmd=repview&type=479-1129&name=5_538747_PDF."},{"issue":"10","key":"10.1016\/j.clindermatol.2020.12.013_bib0043","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/annrheumdis-2020-217522","article-title":"Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis","volume":"79","author":"Megremis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0044","article-title":"Myositis as a manifestation of SARS-CoV-2","author":"Beydon","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0045","article-title":"Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future","author":"Wang","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0046","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"Won Huh","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0047","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/rheumatology\/39.8.914","article-title":"Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation","volume":"39","author":"Selva-O'Callaghan","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0048","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Zahr","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0049","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0051","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.thromres.2020.05.039","article-title":"Thrombosis risk associated with COVID-19 infection. A scoping review","volume":"192","author":"Al-Ani","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0052","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/BOR.0000000000000442","article-title":"Cardiovascular involvement in myositis","volume":"29","author":"Diederichsen","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0053","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S157085","article-title":"Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis","volume":"14","author":"Li","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0054","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2014-205800","article-title":"Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study","volume":"75","author":"Carruthers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamadermatol.2014.5070","article-title":"Amyopathic dermatomyositis-related thrombophilia","volume":"151","author":"Kirchhof","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0056","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4067\/S0034-98872016000200012","article-title":"Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sist\u00e9micas [Hydroxychloroquine for autoimmune diseases","volume":"144","author":"Danza","year":"2016","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0057","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000396","article-title":"Thoughts on COVID-19 and autoimmune diseases","volume":"7","author":"Askanase","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0058","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0059","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0061","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0062","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0063","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s10067-020-05193-2","article-title":"The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress","volume":"39","author":"Orlandi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0064","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0065","article-title":"Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab","author":"Avouac","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0066","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0067","doi-asserted-by":"crossref","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","article-title":"Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus disease 2019\u2014United States, February 12-March 28, 2020","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0068","first-page":"ccc023","article-title":"Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic","author":"Littlejohn","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0069","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0070","first-page":"e13686","article-title":"Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days","volume":"2020","author":"Karadag","year":"2020","journal-title":"Dermatol Therapy"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0071","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0072","doi-asserted-by":"crossref","first-page":"e6376","DOI":"10.1097\/MD.0000000000006376","article-title":"Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV)","volume":"96","author":"Pastuszczak","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0073","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0074","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1534734618804982","article-title":"Vasculitis\u2014what do we have to know? A review of literature","volume":"17","author":"Shavit","year":"2018","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0075","first-page":"e13544","article-title":"COVID-19 with dermatologic manifestations and implications: an unfolding conundrum","author":"Almutairi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0076","first-page":"e16","article-title":"Five common skin manifestations of COVID-19 identified","volume":"183","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0077","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16469","article-title":"Viral exanthem in COVID-19, a clinical enigma with biological significance","volume":"34","author":"Su","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0078","article-title":"Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia","volume":"28","author":"Zhang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0079","first-page":"e13766","article-title":"Schamberg-like purpuric eruptions and tonsillitis in mild COVID-19","author":"Wollina","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0080","article-title":"Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia","author":"Guilpain","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0081","article-title":"Mild COVID-19 in ANCA-associated vasculitis treated with rituximab","author":"Su\u00e1rez-D\u00edaz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.12.013_bib0082","series-title":"Infezione da Coronavirus, Vademecum per i pazienti affetti da malattie bollose e malattie autoimmuni","year":"2020"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:21Z","timestamp":1760033901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20302480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0738081X20302480"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.013","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune connective tissue diseases in the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}